Lupin (NSE:LUPIN, BOM:500257) has received two observations from the US Food and Drug Administration (US FDA) after the inspection of its manufacturing facility in Ankleshwar, India, according to a filing to the stock exchanges on Saturday.
Shares of the company fell over 2% in Monday's trade.
The inspection was carried out by the regulator from March 2 to March 7.
The company stated that it will address the observations and respond to the US FDA within the given timeframe.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.